US 12,221,449 B2
Pyrrolopyrimidine derivative and use thereof
Xuejun Zhang, Hubei (CN); Dabing Ye, Hubei (CN); Lie Li, Hubei (CN); Jie Shen, Hubei (CN); Xiaohua Ding, Hubei (CN); Hongna Sun, Hubei (CN); Zhe Liu, Hubei (CN); Yang Zang, Hubei (CN); and Yonggang Wei, Hubei (CN)
Assigned to WUHAN HUMANWELL INNOVATIVE DRUG RESEARCH AND DEVELOPMENT CENTER LIMITED COMPANY, Hubei (CN)
Appl. No. 17/423,482
Filed by WUHAN HUMANWELL INNOVATIVE DRUG RESEARCH AND DEVELOPMENT CENTER LIMITED COMPANY, Hubei (CN)
PCT Filed Jan. 22, 2020, PCT No. PCT/CN2020/073859
§ 371(c)(1), (2) Date Jul. 16, 2021,
PCT Pub. No. WO2020/156459, PCT Pub. Date Aug. 6, 2020.
Claims priority of application No. 201910106140.X (CN), filed on Feb. 1, 2019; and application No. 201910572538.2 (CN), filed on Jun. 26, 2019.
Prior Publication US 2022/0064172 A1, Mar. 3, 2022
Int. Cl. C07D 487/04 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01)
CPC C07D 487/04 (2013.01) [A61K 31/519 (2013.01); A61K 45/06 (2013.01)] 13 Claims
 
1. A compound, being a compound represented by Formula I; or being a tautomer, a stereoisomer, a hydrate, a solvate, a salt, or a prodrug of the compound represented by Formula I,

OG Complex Work Unit Chemistry
wherein,
R1 and R2 are each independently selected from —H or —CH3,
provided that:
when R1 and R2 are not —H simultaneously; or
when R1 and R2 are not —CH3 simultaneously.